Chicago, IL – The 2026 American Society of Clinical Oncology (ASCO) annual meeting, a cornerstone event for oncological advancements, has concluded, leaving a significant trail of promising data and renewed hope in the fight against blood cancers. This year’s conference showcased a dynamic landscape of innovation, with key readouts spanning both prevalent hematological malignancies like chronic lymphocytic leukemia (CLL) and multiple myeloma, as well as a critical focus on rare and challenging conditions such as myelofibrosis and Waldenström macroglobulinemia. Clinical Trials Arena has meticulously reviewed the most impactful developments, highlighting therapies that are poised to redefine treatment paradigms and improve patient outcomes.
Beigene’s Brukinsa Achieves Sustained Long-Term Control in Chronic Lymphocytic Leukemia
A major highlight from ASCO 2026 emerged from the Phase III SEQUOIA study (NCT03336333), which presented compelling 78-month follow-up data for BeiGene’s Bruton’s tyrosine kinase (BTK) inhibitor, Brukinsa (zanubrutinib). The study, which compared Brukinsa against the standard of care (SoC) combination of bendamustine and rituximab (BR) in patients with frontline chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), demonstrated remarkable long-term disease control.
Supporting Data:
At the 78-month mark, Brukinsa exhibited a progression-free survival (PFS) rate of an impressive 71.8%, significantly outperforming the 31% PFS observed in the BR arm. This disparity was even more pronounced in a specific subgroup of patients harboring mutations in the gene segments associated with B-cell antibody production, where 81.8% remained progression-free with Brukinsa compared to 45.1% with BR. Furthermore, trends indicated a favorable time to next treatment with Brukinsa, underscoring its durable efficacy. The drug’s safety profile remained consistent with previous observations, reassuring clinicians about its tolerability.
Official Response:
Dr. Amit Agarwal, BeiGene’s Chief Medical Officer for Hematology, emphasized the significance of these long-term findings. "Our data at ASCO show that Brukinsa continues to deliver sustained disease control, which can give physicians and patients confidence to stay the course," Dr. Agarwal stated. He further elaborated on the strength of real-world analyses, asserting, "Robust, real-world analyses reinforce its role as a best-in-class BTK inhibitor, with data favoring Brukinsa over other BTK inhibitors across several efficacy and safety endpoints." This sentiment suggests a strategic positioning of Brukinsa as a leading option in the BTK inhibitor class.
Implications:
The extended follow-up data for Brukinsa in CLL/SLL is a powerful testament to its enduring efficacy. For a disease often managed chronically, sustained disease control is paramount. These results not only solidify Brukinsa’s position as a frontline treatment option but also suggest a potential shift away from traditional chemotherapy-based regimens towards more targeted and durable therapies. The comparison against Imbruvica (ibrutinib) and Calquence (acalabrutinib) in real-world analyses further strengthens BeiGene’s claim of Brukinsa’s best-in-class potential, indicating a significant competitive advantage.
Karyopharm’s Xpovio Shows Promising Additive Benefit in Myelofibrosis
In the challenging landscape of myelofibrosis, a rare and debilitating bone marrow cancer, Karyopharm Therapeutics presented encouraging data for its exportin-1 inhibitor, Xpovio (selinexor). The Phase III SENTRY trial (NCT04562389) evaluated Xpovio in combination with standard of care Janus kinase (JAK) inhibitors, such as Pfizer’s Jakafi (ruxolitinib), in symptomatic patients with myelofibrosis who require treatment.
Chronology:
The SENTRY trial was designed to assess the combinatory potential of Xpovio with Jakafi in JAK inhibitor-naïve myelofibrosis patients. The primary endpoint focused on spleen volume reduction, while a secondary endpoint examined symptom response.
Supporting Data:
A topline readout from the SENTRY trial revealed that 50% of patients receiving the Xpovio-Jakafi combination achieved a 35% or greater reduction in spleen volume, surpassing the 28% observed with Jakafi monotherapy. This met one of the trial’s co-primary endpoints. Notably, an early overall survival (OS) signal favoring the combination therapy was also observed (p=0.0222), which Karyopharm intends to follow to maturity for a more definitive assessment.
However, the trial did not meet its key secondary endpoint related to symptom response. Patients on the combination therapy experienced a 10.86-point improvement in symptom scores from baseline to week 24, which was slightly lower than the 9.89-point improvement seen in the Jakafi monotherapy group. Treatment discontinuation rates were also marginally higher in the Xpovio-Jakafi arm, with 14.5% discontinuing compared to 8.6% in the Jakafi-only arm.
Official Response:
While Karyopharm has not issued a formal statement specifically for this readout, the presentation of the data at ASCO signifies their continued commitment to developing Xpovio for myelofibrosis. The observation of an early survival benefit, despite missing the secondary symptom endpoint, is a critical point of interest.
Implications:
The SENTRY trial data presents a nuanced yet promising outlook for Xpovio in myelofibrosis. The achievement of the spleen volume reduction endpoint and the intriguing early survival signal suggest that the combination therapy holds potential to improve outcomes beyond current standards. The fact that the combination met a primary endpoint, even with a less robust symptom response and slightly higher discontinuation rate, indicates a careful balancing act between efficacy and tolerability. As noted by Andrew Kuykendall of the Moffitt Cancer Center, the "unprecedented early survival benefit linked to Selinexor-ruxolitinib seen in the SENTRY trial" warrants further investigation as more data emerges, potentially paving the way for a new therapeutic strategy in this rare disease.
Cellectar Biosciences’ Iopofosine Shows Remarkable Efficacy in Waldenström Macroglobulinemia
In a significant advancement for rare blood cancers, Cellectar Biosciences has announced its intention to seek accelerated US approval for its radiopharmaceutical and phospholipid-drug conjugate (PDC), iopofosine I 131, following a successful Phase IIb outcome in relapsed or refractory (R/R) Waldenström macroglobulinemia (WM).
Chronology:
The CLOVER WaM study (NCT02952508) was a Phase IIb trial designed to evaluate the efficacy and safety of iopofosine I 131 in R/R patients with symptomatic WM who had undergone more than two prior therapies. A key design element was the administration of the radiopharmaceutical immediately following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor.
Supporting Data:
The CLOVER WaM study demonstrated exceptional results in the 24 enrolled patients. The overall response rate (ORR) was an impressive 87.5%, with a substantial 79.2% of patients achieving a partial response (PR) or better. The median duration of response (DOR) was 16 months, with a remarkable 20% of patients experiencing a DOR of 30 months or longer. Crucially, iopofosine I 131 was generally well-tolerated, with the only treatment-related side effect reaching Grade 3 or higher being cytopenia.
Official Response:
Jarrod Longcor, Cellectar’s Chief Operating Officer, expressed optimism about the findings. "These outcomes give us even greater confidence in the potential of iopofosine to be effective in an earlier line setting as will be evaluated in the planned Phase 3 confirmatory study," Longcor stated. This indicates a clear regulatory pathway and a commitment to further validating the drug’s benefit.
Implications:
The success of iopofosine I 131 in the CLOVER WaM study represents a critical step forward for patients with WM, particularly those who have progressed on or are refractory to BTK inhibitors. The high ORR and durable responses observed address a significant unmet need, as patients with post-BTK inhibitor disease often face limited treatment options and rapid progression. Cellectar’s proactive move towards seeking accelerated approval underscores the urgency and potential impact of this therapy. The planned confirmatory Phase III study, expected to commence in Q4 2026, will be crucial in solidifying iopofosine’s place in the WM treatment armamentarium.
AL Amyloidosis: A Glimmer of Hope with Novel Approaches
Light chain (AL) amyloidosis, a rare and often life-threatening condition, also saw significant developments at ASCO 2026, with both Regeneron and AstraZeneca presenting data on their late-stage investigational therapies.
Chronology:
The presentations focused on novel therapeutic modalities aimed at tackling the underlying causes of AL amyloidosis, moving beyond traditional plasma cell-directed therapies.
Supporting Data:
AstraZeneca’s anti-fibril therapy, anselamimab, while not meeting its primary endpoint in the global CARES program, did demonstrate statistically significant benefits over placebo in adults with advanced kappa AL amyloidosis when used as a frontline therapy in addition to SoC. This suggests a potential role for anselamimab in specific patient populations.
Regeneron’s BCMA-CD3-directed bispecific antibody, linvoseltamab, is being explored in the Phase I/II LINKER AL-2 study (NCT06292780). In a cohort of 20 patients with R/R AL amyloidosis, none experienced dose-limiting toxicity or immune effector cell-associated neurotoxicity syndrome (ICANS). While one patient died due to a ventricular fibrillation event, the investigator deemed it unrelated to the study drug. Importantly, promising early efficacy was observed, with 100% and 92.3% of patients receiving the 80mg and 240mg doses, respectively, achieving a hematologic objective response (hOR).
Official Response:
Jill Condello, Senior VP of Medical Strategy at OPEN Health, commented on the significance of these updates via LinkedIn, stating that the data from AstraZeneca and Regeneron "pointed to new, biology-driven approaches in a space that has had very few options beyond standard plasma-cell-directed regimens." This highlights the excitement surrounding these novel mechanisms of action.
Implications:
The current landscape for AL amyloidosis treatment is dominated by Johnson & Johnson’s Darzalex Faspro (daratumumab and hyaluronidase-fihj), the sole approved therapy specifically for this condition. The limited therapeutic options underscore the critical need for new treatments. The data presented for anselamimab and linvoseltamab, despite their differing trajectories, indicate a promising shift towards novel therapeutic strategies. Anselamimab’s subgroup benefit suggests targeted application, while linvoseltamab’s early efficacy and safety profile, particularly in R/R disease, offers substantial hope for a much-needed advancement in a challenging area of hematologic oncology. These developments signal a move towards more nuanced and potentially more effective treatments for AL amyloidosis patients.
The ASCO 2026 meeting has undeniably set a robust agenda for the future of blood cancer treatment. The sustained efficacy of established therapies like Brukinsa, coupled with the emergence of promising new agents for challenging conditions like myelofibrosis and Waldenström macroglobulinemia, paints a brighter picture for patients worldwide. Continued research and development, as showcased at this pivotal conference, remain essential in the ongoing battle against these complex diseases.
About the Author
